Compare Nokia Corp (NOK) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nokia Corp vs Novo Nordisk A/S — how do they compare? Nokia Corp trades at $11.08 (market cap $56.70B), while Novo Nordisk A/S trades at $49.35 (market cap $220.53B). The key difference: Novo Nordisk A/S is far larger — about 3.9× Nokia Corp's market cap, and Novo Nordisk A/S pays the higher dividend (3.63%). Which is the better fit depends on your goals.
| NOK | NVO | |
|---|---|---|
Market Cap | $56.70B | $220.53B |
Sector | Technology | Health |
52-Week High | $16.83 | $71.70 |
52-Week Low | $4.05 | $35.29 |
Enterprise Value | $53.51B | $239.49B |
Dividend Yield | 1.63% | 3.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nokia (NOK) trades at $10.65, up 5.24% on the day, with a bullish analyst consensus price target of $18.00 representing significant upside. Recent earnings show mixed results with a Q1 2026 miss but Q3 and Q4 2025 beats. The company is pivoting toward AI and 5G infrastructure, evidenced by new partnerships and strong revenue growth in these segments. Technical indicators are mixed, with oscillators bullish but moving averages bearish, suggesting near-term consolidation.
The outlook is cautiously optimistic, driven by AI networking demand and strategic deals, but risks include intense competition and execution challenges. Valuation appears stretched with a P/E of 63.22, requiring sustained earnings growth to justify current levels. The stock offers potential for long-term growth if AI initiatives deliver, but near-term volatility is likely.
Novo Nordisk (NVO) trades at $49.38, down 1.87% amid legal action against Eli Lilly over GLP-1 drug advertising. The stock maintains strong fundamentals with a P/E of 11.91 and robust profitability margins (net income margin 37.2%, ROE 71.4%). Recent quarterly earnings consistently beat expectations, with Q1 2026 EPS of $1.04 surpassing the $0.87 estimate. Technical indicators show a bullish moving average signal while oscillators remain neutral, with key support at $48.
Outlook remains positive given strong earnings momentum and market leadership in GLP-1 drugs, though legal risks and competitive pressures from Eli Lilly pose near-term headwinds. Analyst consensus is bullish (57.9% buy ratings) with projected revenue growth to $327.8B in 2026. Key risks include litigation outcomes and market share competition in the weight-loss drug segment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nokia Corp
Nokia is a leading vendor in the telecommunications equipment industry. The company's network business derives revenue from selling wireless and fixed-line hardware, software, and services. Nokia's technology segment licenses its patent portfolio to handset manufacturers and makes royalties from Nokia-branded cellphones. The company, headquartered in Espoo, Finland, operates on a global scale, with most of its revenue from communication service providers.
Read more on NOK →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
